Four PARP inhibitors (PARPi), olaparib, rucaparib, niraparib and talazoparib, have been approved by the US FDA for the treatment of breast cancer, ovarian cancer and peritoneal cancer.49 The gene discussed is PARP1; the disease is ovarian carcinoma.